EUCTR2020-005580-32-AT进行中（未招募）1 期
Pilot study on silibinin as a possible therapeutic agent for mildly ill COVID-19 patients
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with mild COVID-19 disease without the need for assisted ventilation
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •Need for assisted ventilation
研究者
相似试验
招募中
3 期
Silymarin in multiple SclerosisTherapeutic effect of silymarin.IRCT20171220037977N1Esfahan University of Medical Sciences60
已完成
2 期
To evaluate the effectiveness of Silymarin (Livergol) on IL-6 levels and size of endometrioma lesionsIRCT20150905023897N5Vice chancellor for research Tarbiat Modares University60
招募中
3 期
The effect of Silymarin on dyslipidemic patients with Alzheimer's diseaseAlzheimer's disease.Alzheimer's disease with late onsetG30.1IRCT20210901052360N1Iran University of Medical Sciences36
招募中
2 期
Beneficial Effect of Silymarin in Ulcerative ColitisUlcerative ColitisNCT06213857Tanta University44
进行中（未招募）
1 期
Sitagliptin is an established diabetes drug medication that acts primarily by stimulating the body’s ability to release insulin, leading to a lowering of blood sugar levels. This clinical trial will examine whether treatment with Sitagliptin can improve both depression and type 2 diabetes togetherDepression in type 2 diabetesMedDRA version: 20.0 Level: PT Classification code 10012378 Term: Depression System Organ Class: 10037175 - Psychiatric disordersMedDRA version: 20.0 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2015-004527-32-GBKing's College London44